1. Home
  2. CABO vs DMAC Comparison

CABO vs DMAC Comparison

Compare CABO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cable One Inc.

CABO

Cable One Inc.

HOLD

Current Price

$50.94

Market Cap

425.5M

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$6.09

Market Cap

347.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CABO
DMAC
Founded
1980
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
425.5M
347.5M
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
CABO
DMAC
Price
$50.94
$6.09
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
$125.67
$15.50
AVG Volume (30 Days)
197.4K
141.6K
Earning Date
04-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
6.12
N/A
Revenue
$1,501,423,000.00
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.83
N/A
P/E Ratio
$9.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$45.37
$3.48
52 Week High
$180.74
$10.42

Technical Indicators

Market Signals
Indicator
CABO
DMAC
Relative Strength Index (RSI) 34.88 46.41
Support Level $45.37 $5.76
Resistance Level $117.15 $6.18
Average True Range (ATR) 4.67 0.32
MACD 1.66 0.03
Stochastic Oscillator 34.60 46.86

Price Performance

Historical Comparison
CABO
DMAC

About CABO Cable One Inc.

Cable One Inc is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. The company derives majority of its revenue from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: